Abstract
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare autosomal dominant hereditary cancer syndrome characterized by a predisposition to cutaneous leiomyomas, uterine leiomyomas, and renal cell carcinoma (RCC). It is known to be caused by germline mutations of the fumarate hydratase (FH) gene, which encodes an enzyme component of the citric acid cycle and catalyzes the conversion of fumarate to L-malate. Currently, there is no standardized treatment for HLRCC, which may be due in part to a lack of understanding of the underlying mechanisms. Here, the underlying molecular mechanisms by which the inactivation of FH causes HLRCC are discussed. Additionally, potential therapeutic pharmacological strategies are also summarized to provide new perspectives for the prevention and treatment of HLRCC.
Introduction
Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is an aggressive cancer syndrome resulting from germline mutations in the FH gene. While the syndrome presents with benign skin and uterine growths, the associated renal cell carcinoma is notably aggressive and prone to early metastasis. Affecting approximately 1 in 200,000 individuals, HLRCC is often misdiagnosed as more common renal cancers, leading to suboptimal treatment outcomes. This review synthesizes current knowledge on the metabolic hijacking driven by FH deficiency and evaluates emerging systemic therapies.
Molecular Pathogenesis: Fumarate as an Oncometabolite
The hallmark of HLRCC is the loss of fumarate hydratase activity, leading to a massive accumulation of fumarate. This metabolite acts as an "oncometabolite" by competitively inhibiting alpha-ketoglutarate-dependent dioxygenases. This inhibition prevents the degradation of Hypoxia-Inducible Factor 1-alpha (HIF-1α), creating a state of "pseudohypoxia" that drives angiogenesis and glycolysis even in well-oxygenated conditions.
Furthermore, excess fumarate induces the chemical modification of KEAP1 through a process known as succination. This modification prevents KEAP1 from targeting NRF2 for degradation, resulting in the constitutive activation of the NRF2 antioxidant pathway. This pathway provides a survival advantage to cancer cells by protecting them from oxidative stress.
Genomic Instability and Epigenetic Alterations
FH-deficient cells exhibit significant genomic and epigenetic alterations. High levels of fumarate inhibit TET enzymes, leading to DNA hypermethylation and the silencing of the miR-200 family. This silencing promotes the Epithelial-to-Mesenchymal Transition (EMT), enhancing the invasive potential of the tumor cells.
Crucially, FH has been found to play a direct role in the nucleus. In response to DNA damage, FH translocates to the nucleus to facilitate double-strand break repair. In HLRCC, the absence of functional FH leads to impaired DNA repair, creating a "BRCA-ness" phenotype. This defect renders HLRCC cells particularly sensitive to PARP inhibitors, a concept known as synthetic lethality.
Clinical Management and Systemic Therapies
Historically, HLRCC has been resistant to standard clear-cell RCC treatments. However, targeted combination therapies are showing significant promise:
- Bevacizumab and Erlotinib: This combination targets both the VEGF and EGFR pathways. The AVATAR trial demonstrated an impressive Objective Response Rate (ORR) of 65% and a median progression-free survival (PFS) of 24.2 months, making it a current front-line consideration.
- Metabolic Targeting: Preclinical studies suggest that combining agents like Vandetanib with Metformin can create a synergistic "double-hit" on the tumor's metabolic vulnerabilities.
- Immunotherapy: Although HLRCC typically shows low PD-L1 expression, case reports have documented complete responses to dual checkpoint inhibition (e.g., Nivolumab plus Ipilimumab) in some patients.
Conclusion
The transition of HLRCC research from basic metabolic biochemistry to clinical application is yielding new hope for patients. While the rarity of the disease limits large-scale Phase III trials, the identification of fumarate-driven pathways has opened doors to targeted therapies and the exploitation of synthetic lethality. Future efforts must focus on overcoming resistance mechanisms and standardizing treatment protocols to improve the prognosis of this aggressive syndrome.
Summary updated